Thermo Fisher Launches Adolescent Alopecia Areata Registry
Thermo Fisher Scientific Inc., the global leader in serving science, has announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry. This initiative addresses a significant unmet need for real-world, adolescent-specific data on alopecia areata, an autoimmune disease that causes patchy or complete hair loss on the scalp and other parts of the […]
Thermo Fisher Partners with X-ELIO for Renewable Energy
Thermo Fisher Scientific has taken a significant step toward achieving its sustainability goals by signing a 10-year virtual power purchase agreement (VPPA) with renewable energy developer X-ELIO. This agreement supports the Lorca solar project, which is set to become operational in 2026 and aims to increase access to renewable electricity for Thermo Fisher and its […]
New Data Shows Gazyva's Superiority in Lupus Nephritis
The New England Journal of Medicine has published detailed findings from Roche’s Phase III REGENCY trial, which demonstrated the superiority of Gazyva®/Gazyvaro® (obinutuzumab) in combination with standard therapy for treating active lupus nephritis (LN). The trial shows a compelling improvement in the complete renal response (CRR) rate, with nearly half of the patients achieving CRR […]
FDA Approves Roche’s Susvimo for Diabetic Macular Edema
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL as the first and only continuous delivery treatment for diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes. This groundbreaking approval provides a less burdensome alternative to standard-of-care eye injections, which often […]
EYLEA HD® Phase 3 Trial Yields Promising Results
Regeneron Pharmaceuticals, Inc. announced promising results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for treating macular edema in patients with retinal vein occlusion (RVO). The results were presented during the Angiogenesis 2025 annual meeting, marking a significant advancement in addressing the treatment challenges faced by RVO patients. Retinal vein […]
Pfizer's BRAFTOVI Improves Survival in Phase 3 Trial
Pfizer has announced groundbreaking results from the Phase 3 BREAKWATER trial, showcasing the effectiveness of its BRAFTOVI® (encorafenib) combination regimen in the treatment of metastatic colorectal cancer (mCRC) with the BRAF V600E mutation. The trial highlights significant improvements in both progression-free survival (PFS) and overall survival (OS), establishing BRAFTOVI as a potential new standard of […]
FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors
FlyPharma, the leading platform for the pharmaceutical logistics and supply chain industry, is thrilled to announce its ninth European conference, which will take place in Amsterdam from October 8-9, 2025. The FlyPharma Amsterdam 2025 conference will convene industry experts to explore the unique challenges and opportunities facing the region and beyond. In a first for FlyPharma, this […]
Neopac Becomes First European Tube Manufacturer to Achieve RecyClass EN 15343 Certification
Oberdiessbach, Switzerland – Neopac, a global provider of high-quality packaging and dosing applications for pharma, beauty and oral care, has successfully passed the RecyClass EN 15343 Audit at its manufacturing site in Debrecen, Hungary. Neopac is the first tube manufacturer in Europe to achieve this prominent certification, underscoring the company’s commitment to sustainability and traceability […]
ACD/Labs Releases State-of-the-Industry Report Highlighting Trends in Chemical Structure Elucidation & Verification
Toronto, CANADA—ACD/Labs, an informatics company that develops and commercializes software in support of digitalized R&D, today released its 2025 Structure Elucidation & Verification Report. Distilled from the experience and expertise of hundreds of researchers gathered at the ACD/Labs’ annual virtual symposium in Q4 2024, the report discusses how trends have shifted since 2022; and how […]
Synexa Life Sciences Achieves Highest Level My Green Lab Certification, Reinforcing Commitment to Lab Sustainability
[LEIDEN, NL] – Life Science Newswire – Synexa Life Sciences, a global provider of biomarker and bioanalytical solutions to the pharmaceutical, biotech, and CRO industries, has proudly achieved the My Green Lab Certification at the highest ‘Green’ level at its Cape Town, South Africa facility. Laboratories play a crucial role in advancing healthcare but are […]
